Search results
Results From The WOW.Com Content Network
World map of annual cannabis prevalence. This is a list of the annual prevalence of cannabis use by country (including some territories) as a percentage of the population. The indicator is an "annual prevalence" rate which is the percentage of the youth and adult population who have consumed cannabis at least once in the past survey year.
Lifetime prevalence of cannabis use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population. Data taken from European Monitoring Centre for Drugs and Drug Addiction (see Commons image page for latest sourcing info). See the table for what percent of an age range used cannabis by country.
Permission is granted to copy, distribute and/or modify this document under the terms of the GNU Free Documentation License, Version 1.2 only as published by the Free Software Foundation; with no Invariant Sections, no Front-Cover Texts, and no Back-Cover Texts.
Cannabis (/ ˈ k æ n ə b ɪ s /) [2] is a genus of flowering plants in the family Cannabaceae that is widely accepted as being indigenous to and originating from the continent of Asia. [3] [4] [5] However, the number of species is disputed, with as many as three species being recognized: Cannabis sativa, C. indica, and C. ruderalis.
THC, the main psychoactive component of cannabis, may only be detectable in saliva and oral fluid for 2–24 hours in most cases. [8] [9] The main metabolite excreted in the urine is 11-Nor-9-carboxy-THC, also known as THC-COOH. Most cannabis drug tests yield a positive result when the concentration of THC-COOH in urine exceeds 50 ng/mL. [10]
Legal cannabis (marijuana) product. Overconsumption and reliance could lead to cannabis-induced amotivational syndrome. The term amotivational syndrome was first devised to understand and explain the diminished drive and desire to work or compete among the population of youth who are frequent consumers of cannabis and has since been researched through various methodological studies with this ...
Clinical endocannabinoid deficiency (CECD) is a medical theory that proposes that a deficiency of endocannabinoids is the underlying pathophysiology of migraines, fibromyalgia, and irritable bowel syndrome. [1] [2] The deficiency may sometimes start in the womb as a result of maternal obesity. [3]
Cannabis was commonly sold in tincture form by Parke-Davis, Eli Lilly, E. R. Squibb & Sons, and other drug manufacturers. [10] [11] By the end of the 19th century, the use of cannabis in medicine had declined due to a number of factors, including difficulty in controlling dosages and the rise in popularity of synthetic and opium-derived drugs. [9]